Neteo Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule inhibitors targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) for the treatment of neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease). The company was founded with a mission to address neuroinflammation, a key driver of neurodegeneration that contributes to dopaminergic neuron loss in the substantia nigra.
...
NetEO Therapeutics
Overview
Mermaid diagram (expand to render)
Neteo Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule inhibitors targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) for the treatment of neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease). The company was founded with a mission to address neuroinflammation, a key driver of neurodegeneration that contributes to dopaminergic neuron loss in the substantia nigra.
Company Profile
| Attribute | Value | |-----------|-------| | Founded | 2019 | | Headquarters | Boston, Massachusetts, USA | | CEO | Dr. Sarah Chen | | Funding | Series B ($45M, 2023) | | Focus | NLRP3 inflammasome inhibitors | | Stage | Preclinical/Phase 1 |
Science and Technology
NLRP3 Inflammasome Targeting
Neteo's platform focuses on developing small molecule inhibitors that target the NACHT domain of NLRP3, preventing inflammasome assembly and subsequent activation of caspase-1 and release of pro-inflammatory cytokines [IL-1β](/proteins/il1b) and IL-18. The company's approach is distinct in its focus on brain-penetrant molecules designed specifically for CNS applications.
Mechanism of Action
The NLRP3 inflammasome plays a critical role in Parkinson's disease pathology:
Activation triggers: Alpha-synuclein aggregates, mitochondrial ROS, and ATP release from damaged neurons activate microglia
Inflammasome assembly: NLRP3 oligomerizes and recruits ASC (PYCARD), forming the inflammasome complex
Caspase-1 activation: Pro-caspase-1 is recruited and activated
Cytokine release: Active caspase-1 cleaves pro-IL-1β and pro-IL-18 to their mature forms
Neuroinflammation: Released cytokines promote microglial activation and dopaminergic neuron death
Neteo's inhibitors block this pathway at the NLRP3 oligomerization step, preventing the downstream inflammatory cascade that drives disease progression.
Pipeline
Parkinson's Disease Program
| Drug | Mechanism | Development Stage | Status | |------|-----------|-------------------|--------| | NT-001 | NLRP3 direct inhibitor | Preclinical | IND-enabling | | NT-002 | NLRP3/BTK dual inhibitor | Discovery | Lead optimization |
NT-001
NT-001 is Neteo's lead NLRP3 inhibitor program for Parkinson's disease. Key features:
Target: NLRP3 NACHT domain ATPase activity
Selectivity: >50-fold selective over related NLRs (NLRP1, NLRP2, NLRC4)
BBB penetration: Designed for CNS exposure; logBB ~0.4